Navigation Links
Actavis Launches Generic Keppra XR® Tablets in the U.S.
Date:9/15/2011

MORRISTOWN, N.J., Sept. 15, 2011 /PRNewswire/ -- Actavis, an international generic pharmaceutical company, today announced that it has received FDA approval of Levetiracetam Extended-Release Tablets, a generic equivalent of Keppra XR®.  Shipping commenced immediately following approval.

Keppra XR® had US total sales of approximately $161 million for the 12 months ending June 30, 2011, according to IMS Health.  

About Actavis:

Actavis Inc. is the US distributor of the product and the U.S. subsidiary of Actavis Group hf.  Approximately one third of Actavis Group hf's sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis Inc. has U.S. manufacturing facilities in Elizabeth, NJ and Lincolnton, NC. Actavis also has research and development facilities in Elizabeth, NJ, Owings Mills, MD and Sunrise, FL.

Actavis Group hf is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals.  The company has operations in 40 countries, with more than 10,500 employees.

Keppra XR ® is a trademark owned by a party other than Actavis.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
2. Actavis Launches Oxymorphone Hydrochloride Extended-Release Tablets, CII in the U.S.
3. Actavis Hails U.S. Supreme Court Decision in Labeling Cases
4. Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S.
5. Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S.
6. Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S.
7. Actavis Receives Approval of Pantoprazole Sodium Delayed-Release Tablets, USP in the U.S.
8. Actavis Encourages Consumers to Return Fentanyl Transdermal System 25 mcg/h
9. Actavis Inc. Issues a Voluntary Recall of 18 Lots of Fentanyl Transdermal System 25 mcg/h
10. Actavis Receives Approval of Zolpidem Tartrate Extended-Release Tablets, USP 6.25mg CIV in the U.S. with 180-Day Marketing Exclusivity
11. Actavis Receives Approval of Losartan Potassium Tablets, USP in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... The global  pacemaker market  is expected to reach USD 12.3 billion ... heightening prevalence of cardiac conditions coupled with the availability of medical coverage is ... enhancements in these devices are supporting the expansion of this vertical. ... ... Grand View Research Logo ...
(Date:1/19/2017)... -- ViewRay, Inc. (Nasdaq: VRAY ), makers ... radiation therapy system, announced today that it has raised ... a private placement of its common stock and ... was joined by certain of ViewRay,s existing investors, ... and an additional new institutional investor, Acuta Capital ...
(Date:1/19/2017)...  Magnetic Insight Inc., leader in magnetic particle ... with inviCRO LLC to develop intuitive image analysis ... on inviCRO,s VivoQuant™ visualization and post processing software ... MPI solution package with the Momentum MPI imaging ... in vivo. MPI is a groundbreaking ...
Breaking Medicine Technology:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... wellness products to enhance people’s everyday lives, recently attended the January ECRM Trade ... , ATP Science is known for its large range of supplements that keep ...
(Date:1/20/2017)... ... 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: a unique ... Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of ... interacting with countless women who had little knowledge of the female characters portrayed in ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Christmas in Suffolk”: a story of love, ... who lives in Lafayette, Indiana where she works in a daycare and looks for ... , Published by Christian Faith Publishing, Sara Seymour’s new book is an adventure of ...
(Date:1/19/2017)... ... January 20, 2017 , ... Today, the Centers for Medicare & Medicaid ... CMS’s Alternative Payment Models (APMs) in 2017. Clinicians who participate in APMs are paid ... important part of the Administration’s effort to build a system that delivers better care ...
(Date:1/19/2017)... ... 19, 2017 , ... This month, the CEO and Clinical Director of Sober ... rehab center in Delray Beach, Florida has been changed from Sober Living Outpatient to ... Philip Seymour Hoffman and Chris Farley are dying from heroin overdoses, but thousands of ...
Breaking Medicine News(10 mins):